Impact of Everolimus on HIV Persistence Post Kidney or Liver Transplant
Status:
Completed
Trial end date:
2018-01-31
Target enrollment:
Participant gender:
Summary
Zortress (everolimus), the 40-O-(2-hydroxyethyl)-derivative of rapamycin, is an mTOR
inhibitor approved for rejection prophylaxis in kidney transplant recipients. mTOR inhibition
may favorably impact the HIV viral reservoir, and we hypothesize that adding everolimus to
the transplant immunosuppressive regimen of HIV positive transplant recipients will decrease
HIV persistence in CD4+ lymphocytes.